A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy

Barbara B Haley, Kiran Batra, Sunati Sahoo, Thomas Froehlich, Dawn Klemow, Nisha Unni, Chul Ahn, Melissa Rodriguez, Melanie Hullings, Arthur E. Frankel

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background: Preclinical breast cancer models with acquired HER2 resistance exhibit decreased proliferation with CDK4/6 inhibition in tumors with intact Rb and low p16 levels. Adding cytotoxic agents like T-DM1 enhances the inhibitory CDK4/6 cytostatic effect. Patients and Methods: A phase I/Ib 3+3 dose escalation/expansion trial of palbociclib and T-DM1 identified 150 mg on days 5 to 18 as the palbociclib maximal tolerated dose combined with day 1 intravenous T-DM1 in 21-day treatment cycles. Patients were previously treated with trastuzumab and a taxane with no limitation on prior therapy lines, including prior pertuzumab, lapitinib, neratinib, and T-DM1. Median age was 54 years and two-thirds were estrogen receptor positive. Primary objectives included maximum tolerated dose as determined by dose-limiting toxicity, and secondary end points of safety, toxicity, response rate, response duration, and progression-free survival. Results: From May 2014 to August 2018, 18 total patients were treated. The median number of cycles was 6.5 (1–22). A maximum tolerated dose was not reached. The most common G3 toxicity of more than 10% incidence was hematologic. Overall response rate (complete response + partial response) was 33% (95% confidence interval, 13%–59%). Median duration of response in responders was not reached and median-progression free survival was 6 months (95% confidence interval, 2.5–11.6). Conclusions: The combination of day 1 T-DM1 and days 5 to 18 palbociclib is safe, tolerable, and active in previously treated HER2-positive relapsed patients. Observed hematologic toxicity is manageable. The trial response rate confirms that a CDK 4/6 inhibitor can resensitize HER2-resistant breast cancer.

Original languageEnglish (US)
Pages (from-to)417-424
Number of pages8
JournalClinical breast cancer
Issue number5
StatePublished - Oct 2021


  • Axis blockade
  • CDK4/6 inhibitors
  • Cyclin D1
  • HER2 resistance
  • Intact Rb

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A Phase I/Ib Trial of PD 0332991 (Palbociclib) and T-DM1 in HER2-Positive Advanced Breast Cancer After Trastuzumab and Taxane Therapy'. Together they form a unique fingerprint.

Cite this